← Research library

Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.

Randomized study in people · 2020

What was studied
142 enrolled; 139 analyzed after moderate–severe traumatic brain injury
Main finding
CAPTAIN II reports improvement in a multidimensional outcome at 90 days with adjunctive treatment.

Day-90 primary composite · MW 0.59; 95% CI 0.52–0.66 · p=0.0119

Reported findings and study design

CAPTAIN II enrolled 142 patients and analyzed 139. The day-90 composite favored Cerebrolysin: MW 0.59 (95% CI 0.52–0.66; p=0.0119).

Population or model 142 enrolled; 139 analyzed after moderate–severe traumatic brain injury

Dose, route and schedule

Cerebrolysin: 50 mL/day for ten days, followed by two further ten-day cycles at 10 mL/day. The indexed abstract does not specify the intervals between cycles.

Protocol source ↗ · Indexed publication abstract

Results · Primary indexed abstract checked
MeasureResultComparison, timing and statistics
Day-90 primary compositeMW 0.59; 95% CI 0.52–0.66p=0.0119
Enrollment / analysis142 enrolled; 139 analyzed

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Single-center trial; a composite benefit does not establish benefit on every outcome. Secondary CAPTAIN reports reuse this cohort.

Source details

Journal publication

Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.

Sources checked

Citation

Randomized trialEnglish abstract

Muresanu DF, Florian S, Hömberg V, Matula C, von Steinbüchel N, Vos PE, von Wild K, Birle C, Muresanu I, Slavoaca D, Rosu OV, Strilciuc S, Vester J. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Study source ↗ · DOI 10.1007/s10072-019-04181-y · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards